Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma

被引：10

作者：

Nakashima, Jun ^{[1
,2
]}

Imaizumi, Yoshitaka ^{[3
]}

Taniguchi, Hiroaki ^{[4
]}

Ando, Koji ^{[1
]}

Iwanaga, Masako ^{[5
]}

Itonaga, Hidehiro ^{[3
]}

Sato, Shinya ^{[3
]}

Sawayama, Yasuhi ^{[3
]}

Hata, Tomoko ^{[1
]}

Yoshida, Shinichiro ^{[2
]}

Moriuchi, Yukiyoshi ^{[4
]}

Miyazaki, Yasushi ^{[1
,3
]}

机构：

[1] Nagasaki Univ, Dept Hematol, Atom Bomb Dis & Hibakusha Med Unit, Grad Sch Biomed Sci, Nagasaki, Japan

[2] Natl Hosp Org Nagasaki Med Ctr, Dept Hematol, Nagasaki, Japan

[3] Nagasaki Univ Hosp, Dept Hematol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan

[4] Sasebo City Gen Med Ctr, Dept Hematol, Nagasaki, Japan

[5] Nagasaki Univ, Dept Frontier Life Sci, Grad Sch Biomed Sci, Nagasaki, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2018年 / 108卷 / 05期

基金：

日本学术振兴会;

关键词：

ATL; Mogamulizumab; Prognostic factors; COMBINATION CHEMOTHERAPY; PROGNOSTIC INDEX; LEUKEMIA/LYMPHOMA; EXPRESSION; CCR4;

D O I：

10.1007/s12185-018-2509-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Adult T-cell leukemia-lymphoma (ATL) is a distinct T-cell malignancy caused by human T-cell leukemia virus type-1; the prognosis is very poor. Mogamulizumab (Moga), an antibody drug for CC chemokine receptor type 4, has been introduced for the treatment of ATL. However, the prognosis of relapsed or refractory ATL remains poor and the characteristics of patients who derive clinical benefit from treatment with Moga remain poorly understood. We analyzed the associations of clinical factors with the outcome after Moga treatment. Forty-five patients treated with Moga monotherapy were evaluated. The median age of the patients was 69 years, and 40% were female. The median overall survival (OS) time was 17.6months and the 2-year OS rate was 43.2%. Number of prior therapies and response to prior therapy were predictive clinical features in univariate analysis for OS. Performance status, corrected serum calcium level, serum lactate dehydrogenase level, Japan Clinical Oncology Group-prognostic index (PI), and simplified ATL-PI at Moga treatment were also associated with the prognosis after Moga monotherapy. Improved understanding of the clinical factors predicting the prognosis after Moga may contribute to improved treatment strategies for ATL.

引用

页码：516 / 523

页数：8